Best of ASCO - 2014 Annual Meeting

 

Welcome

Other/Nonsubtype Specific

Breast Cancer—Metastatic

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.

Cristina Saura

1014

A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).

Juan De La Haba

TPS1114

A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.

Neelima Vidula

TPS1113

A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of pulmonary toxicities in patients with advanced breast cancer treated with everolimus.

Sriman Swarup

e13086

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Anne Patsouris

TPS1112

Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.

Gordon Vansant

1084

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

Wolfgang Eiermann

1070

Androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.

Ingeborg Elisabeth de Kruijff

1087

Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial.

Ahmad Awada

1072

Apatinib plus vinorelbine: A novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.

Peng Yuan

e13096

Association between metastatic free interval and recurrent metastatic breast cancer survival: Findings from the Surveillance, Epidemiology and End Results database.

Enoch Chang

e13069

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Debu Tripathy

TPS1111

Benefits and risks from maintenance therapy after first-line chemotherapy in patients with metastatic breast cancer.

Yunfang Yu

1088

Breast cancer stem cell autoantibodies to identify women with advanced breast cancer.

Sasha E. Stanton

1079

Can a cancer antigen (CA)15-3 directed monitoring strategy be resource sparing in metastatic breast cancer (MBC)?

Santam Chakraborty

e13104

Chemotherapy-induced placental toxicity: The role of vascular toxicity.

Irit Ben-Aharon

e13097

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Priyanka Sharma

1018

Clinical evaluation of germline polymorphisms (SNPs) associated with disease response to capecitabine in metastatic breast cancer (MBC) (TBCRC 015).

Noura Choudhury

1071

Clinicopathological features and prognosis of pregnancy associated breast cancer at Instituto Nacional de Cancerología of Mexico.

Wendy Rossemary Munoz Montano

e13099

Comparative efficacy and acceptability of first-line single-agent chemotherapy in metastatic breast cancer.

Ying Wang

e13082

Comparison of survival-post-treatment of stage 4 v.s. distant recurrent primary breast cancer.

Yoshihiko Kamada

e13067

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).

Neelima Vidula

1020

Comparison of triple negative (TN) and HER2 positive (HER2+) invasive lobular carcinomas (ILCs) to a matched cohort of invasive ductal carcinomas.

Dan Le

e13088

Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).

Mafalda Oliveira

1073

Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).

Huiping Li

1080

Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.

Romualdo Barroso-Sousa

1010

Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.

Makiko Ono

1075

Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies.

Qiang Zhang

1090

Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: An open-label, randomized, multicenter phase III trial.

Jun Cao

1078

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

Eleanor Meisner

1074

EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.

Hope S. Rugo

1069

Establishment and characterization of a circulating tumor cell line from a breast cancer patient.

Pan Zhao

e13062

Estrogen receptor (ER), progesterone receptor (PR) and Her2neu receptor expresssion: Change from baseline to first metastasis in breast cancer—Single center experience from developing country.

Manish Sharma

e13095

Expression of aldehyde deshydrogenase 1 ( ALDH1) in inflammatory breast cancer: A cohort study.

Fouzia Mamouch

e13064

Features associated with long-term survival in metastatic breast cancer.

Natalie Klar

e13074

Immune sidedness of breast cancer: Pilot study of neutrophil/lymphocyte ratio anatomic disparities in breast cancer patients.

Zachary Spigelman

e13094

Impact of bariatric surgery on breast cancer disease burden in the obese breast cancer survivor.

Anne Hudson Blaes

e13072

Kinin system and blood plasma inhibitors as factors of pathogenesis of osteolytic metastases from breast cancer.

Larisa S. Kozlova

e13106

Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.

Erik Hugger Jakobsen

e13077

Local treatment with bisphosphonates to restore activity of α2-macroglobulin and α1-proteinase inhibitor in osteolytic metastases from breast cancer.

Artem A. Barashev

e13105

Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience.

Vera Gorbunova

e13065

Maintenance immunotherapy in patients with metastatic breast cancer (MBC) who have a clinical benefit with chemotherapy. Long-term follow-up of a phase II study.

Francesco Recchia

e13068

Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study.

Marina Elena Cazzaniga

e13076

Multi-omic profiling of metastatic lesions to guide treatment selection: the Side Out 2 trial experience.

Mariaelena Pierobon

1077

Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study.

Giorgio Mustacchi

e13078

Optimizing the timing of eribulin monotherapy for patients with metastatic breast cancer.

Sumito Shingaki

e13063

Overall survival following locoregional surgery of the primary tumor in de novo stage IV breast cancer patients.

Herui Yao

1082

PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.

Francesca Poggio

e13098

Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.

Angelos Koutras

1089

Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.

Binghe Xu

1003

Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) for patients (pts) with locally advanced or metastatic breast cancer (BC): A meta-analysis.

Martin Tio

1076

Polymorphisms of MTHFR and TYMS to predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.

Shaoyan Lin

1085

Predicting tumor evolution through subclonal classification using variant allele frequency clustering in breast cancer.

Parth Shah

e13084

Predictors of survival after loco-regional therapy (LRT) in stage 4 breast cancer (BC).

Anuhya Kommalapati

1083

Prevalence of herbal medicine (HM) use among breast cancer patients treated with chemotherapy, hormone therapy, or targeted therapy.

Helene Langin

e13108

Profile of metastatic breast carcinoma: Single center experience from a developing country.

Manish Sharma

e13102

Prognosis in young women under 40 with brain metastasis from breast cancer.

Ariana Mustillo

1091

Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.

Giacomo Pelizzari

e13079

Racial disparity in breast cancer immune microenvironment.

Ahmed Elkhanany

1081

Racial/ethnic disparities in skeletal-related events among women treated with bisphosphonate therapy for bone metastasis secondary to breast cancer.

Zhong Zheng

e13092

Real-world clinical outcomes and treatment patterns among metastatic breast cancer (MBC) patients with germline BRCA mutation (gBRCAmut).

Ruben Quek

e13075

Restaging de novo metastatic breast cancer to refine prognostic estimates.

Jennifer Kay Plichta

e13083

Risk of hematological toxicities in patients with advanced breast cancer treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Anita Sultan

e13087

Role of circulating miRNAs in detecting metastasis and having prognostic significance in metastatic breast cancer.

Sofia Agelaki

1086

Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.

Shun Kudo

e13089

Screening the potential long-term survivors among stage IV breast cancer patients from Asian: A multi-center prognostic nomogram based on real-world data.

Jianli Zhao

e13093

SM-88 efficacy and safety in metastatic breast cancers.

Xinhua Zhu

e13100

The difference of clinicopathological characteristics between pure and mixed invasive micropapillary breast carcinoma from China.

Rong Wang

e13107

The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent).

Andrew A. Davis

1019

The integrated genomic and immune landscapes of lethal metastatic breast cancer (MBC).

Leticia De Mattos-Arruda

1009

Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study.

Marina Elena Cazzaniga

e13081

Varying prognostic impact of molecular subtype among young patients with de novo stage IV breast cancer: A population-based cohort study.

Rin Ogiya

e13090

What are the drivers of healthcare cost among patients with metastatic breast cancer (mBC)? Total cost of care analysis to inform value-based reimbursement.

Chakkarin Burudpakdee

1092